What the CJC-1295 research actually measured

How CJC-1295 works: the GHRH receptor to GH to IGF-1

CJC-1295 research begins at one receptor. The compound binds the GHRH receptor on pituitary somatotrophs and activates Gs/cAMP/PKA signaling, which drives CREB-mediated transcription of the GH gene and the pulsatile release of growth hormone ^[2]. The released GH reaches the liver, engages the GH receptor, and through JAK2/STAT5 raises IGF-1 — the downstream hormone that carries much of GH's anabolic signal ^[3].

The origin paper made the mechanism concrete. A series of hGRF(1-29)-albumin bioconjugates was screened in rats; the lead candidate, CJC-1295, combined four DPP-IV-protective substitutions with covalent binding to serum albumin and produced a 4-fold increase in GH area-under-the-curve over two hours versus the unconjugated peptide, with the conjugate detectable in plasma beyond 72 hours ^[2]. That single experiment establishes both halves of the design: protease resistance for stability, albumin conjugation for duration.

What the GH/IGF-1 Research Describes

The clearest human result is the pharmacokinetic one. In healthy adults aged 21-61, single subcutaneous doses of 30 or 60 micrograms/kg produced dose-dependent 2-to-10-fold increases in mean plasma GH for six days or more and 1.5-to-3-fold increases in IGF-1 for 9-11 days; after multiple doses, IGF-1 stayed above baseline as long as 28 days, with an estimated CJC-1295 half-life of 5.8-8.1 days ^[3]. Sustained, dose-dependent, and long — the three properties that define the long-acting analog.

What the research describes is biomarker movement, not validated clinical outcomes. The Sackmann-Sala proteomic study found that CJC-1295 administration shifted the serum proteome in 11 healthy young men — decreased apolipoprotein A1 and a transthyretin isoform, increased an albumin fragment and immunoglobulin species — and the immunoglobulin/albumin-fragment signal tracked linearly with IGF-1 ^[5]. These are candidate biomarkers of GH/IGF-1 axis activation; they are not endpoints like strength, body composition, or longevity, none of which has a controlled CJC-1295 trial in healthy adults.

Does CJC-1295 preserve the natural pulse pattern of growth hormone?

Yes, on the human evidence. In healthy men, a single 60-or-90-microgram/kg subcutaneous dose raised basal GH about 7.5-fold and mean GH by roughly 46%, with IGF-1 up about 45% one week later, while pulsatile GH frequency and magnitude were unchanged ^[1]. Pulsatility persisted under continuous stimulation. The result is reinforced by the broader literature showing that distinct secretagogues exert differential control over pulsatile GH ^[10], and by GHRH-knockout work in which once-daily CJC-1295 normalized growth where less frequent dosing did not ^[4].

CJC-1295 Half-Life: DAC vs No-DAC

The CJC-1295 half life is the property that splits the compound into two. For the DAC variant, the estimated plasma half-life is 5.8-8.1 days in healthy adults, with IGF-1 elevation persisting up to 28 days after multiple doses ^[3]. That multi-day duration comes from covalent conjugation to serum albumin: the effective circulating species is the much larger peptide-albumin complex, near 66 kDa, which clears at roughly albumin's own slow rate rather than the peptide's.

The no-DAC form is a different drug pharmacokinetically. 'Modified GRF 1-29' keeps the four protease-resistant substitutions but lacks the albumin-binding moiety, so it is short-acting — minutes to hours, reflecting native GHRH(1-29) clearance slowed only by the substitutions. The CJC-1295 DAC vs no-DAC page works through the split in full; the short version is that one finding cannot be assumed to transfer to the other.

CJC-1295 Among GHRH Analogs

CJC-1295 belongs to a class. A GHRH analog is a synthetic peptide that mimics growth-hormone-releasing hormone at its receptor; the family includes sermorelin and the FDA-approved tesamorelin (for HIV-associated lipodystrophy), the closest approved-drug comparator to CJC-1295. A 2024/2025 Nature Reviews Endocrinology review synthesized the pharmacology of GHRH and its synthetic analogues — receptor signaling, the rationale for long-acting analog design, and the therapeutic and investigational landscape ^[14].

The class has been studied for tissue-level effects beyond GH release: GHRH agonist analogs promoted wound healing in experimental models ^[11], a GHRH-expression plasmid improved osteoporosis and skin-damage endpoints in aged mice ^[12], and a GHRH analog influenced endogenous GH pulsatility and insulin sensitivity in a clinical study ^[13]. These map the class, not CJC-1295 specifically in humans — a distinction this digest keeps deliberately.

The human record, and where it stops

The human CJC-1295 evidence is real but narrow. Phase 1 and early pharmacokinetic studies in healthy volunteers established the GH/IGF-1 kinetics — the days-long elevation, the 5.8-8.1 day half-life, the preserved pulsatility ^[3][1]. Those are solid results, and they are essentially the whole human dataset. A ConjuChem Phase 2 trial in HIV-associated visceral obesity (NCT00267527) was discontinued, and the long-acting DAC program did not advance further.

What does not exist is as important as what does. There are no large efficacy trials and no long-term safety trials of CJC-1295 in healthy adults; the body-composition, recovery, and anti-aging claims common in community discussion are not backed by controlled outcome data. CJC-1295 is not approved for human use anywhere. The literature also reaches the compound from an unexpected direction: CJC-1295 was structurally identified by high-resolution LC-MS/MS as the active ingredient in an unknown 'GHRH' preparation seized in an anti-doping context ^[6], a reminder that the molecule circulates well outside the clinical trials that first characterized it.